Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5396-5405

  Keshelava, Nino ^a,b   Seeger, Robert C ^a,b   Groshen, Susan ^b   Reynolds, C Patrick ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; TENIPOSIDE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG MONITORING; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GENE AMPLIFICATION; GENES, MYC; HUMANS; KINETICS; NEUROBLASTOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032401845     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Stram, D. O., Matthay, K. K., O'Leary, M., Reynolds, C. F., Haase, G. M., Atkinson, J. B., Brodeur, G. M., and Seeger, R. C. Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J. Clin. Oncol., 14: 2417-2426, 1996.
2. Matthay, K. K., Harris, R., Reynolds, C. P., Shimada, H., Black, T., Stram, D. O., and Seeger, R. C. Improved event-free survival (EFS) for autologous bone marrow transplantation (ABMT) vs chemotherapy in neuroblastoma: a Phase III randomized Children's Cancer Group (CCG) study. Proc. Am. Soc. Clin. Oncol., 17: 525a, 1998.
3. Reynolds, C. P., Villablanca, J. G., Stram, D. O., Harris, R., Seeger, R. C., and Matthay, K. K. 13-cis-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group (CCG) study. Proc. Am. Soc. Clin. Oncol., 17: 2a, 1998.
4. Seeger, R. C., and Reynolds, C. P. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr. Clin. North Am., 38: 393-424, 1991.
5. LaQuaglia, M. P., Kopp, E. B., Spengler, B. A., Meyers, M. B., and Beidler, J. L. Multidrug resistance in human neuroblastoma cells. J. Pediatr. Surg., 26: 1107-1112, 1991.
6. Goldstein, L. J., Fojo, A. T., Ueda, K., Crist, W., Green, A., Brodeur, G., Pastan, I., and Gottesman, M. M. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J. Clin. Oncol., 8: 128-136, 1990.
7. Norris, M. D., Bordow, S. B., Marshal, G. M., Haber, P. S., Cohn, S. L., and Haber, M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med., 334: 231-238, 1996.
8. Kushner, B. H., Vogel, R., Hajdu, S. I., and Helson, L. Metastatic neuroblastoma and testicular involvement. Cancer (Phila.), 56: 1730-1732, 1985.
9. Kennedy, K. A. Hypoxic cells as specific targets for chemotherapy. Anticancer Drug Design, 2: 181-194, 1987.
10. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48: 775-778, 1988.
11. Hayes, F. A., Green, A. A., and Mauer, A. M. Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma. Cancer Res., 37: 3766-3770, 1977.
12. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (Washington DC), 224: 1121-1124, 1984.
13. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.
14. Rosen, N., Reynolds, C. P., Thiele, C. J., Biedler, J. L., and Israel, M. A. Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res., 46: 4139-4142, 1986.
15. Reynolds, C. P., Biedler, J. L., Spengler, B. A., Reynolds, D. A., Ross, R. A., Frenkel, E. P., and Smith, R. G. Characterization of human neuroblastoma cell lines established before and after therapy. J. Natl. Cancer Inst., 76: 375-387, 1986.
16. Wada, R. K., Seeger, R. C., Brodeur, G. M., Einhorn, P. A., Rayner, S. A., Tomayko, M. M., and Reynolds, C. P. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer (Phila.), 72: 3346-3354, 1993.
17. Proffitt, R. T., Tran, J. V., and Reynolds, P. C. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry, 24: 204-213, 1996.
18. Frgala, T., and Proffitt, R. T. A novel 96-well plate cytotoxicity assay based on fluorescence digital imaging microscopy. Proc. Am. Assoc. Cancer Res., 36: 303, 1995.
19. Miyajima, Y., Kato, K., Numata, S., Kudo, K., and Horibe, K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer (Phila.), 75: 2757-2761, 1995.
20. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
21. Sorensen, P. H., Wu, J. K., Berean, K. W., Lim, J. F., Donn, W., Frierson, H. F., Reynolds, C. P., Lopez Terrada, D., and Triche, T. J. Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcoma. Proc. Natl. Acad. Sci. USA, 93: 1038-1043, 1996.
22. Reynolds, C. P., Tomayko, M. M., Donner, L., Helson, L., Seeger, R. C., Triche, T. J., and Brodeur, G. M. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog. Clin. Biol. Res., 271: 291-306, 1988.
23. Whang Peng, J., Triche, T. J., Knutsen, T., Miser, J., Kao Shan, S., Tsai, S., and Israel, M. A. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet. Cytogenet., 21: 185-208, 1986.
24. Crabbe, D. C. G., Peters, J., and Seeger, R. C. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diag. Mol. Pathol., 1: 229-234, 1993.
25. Celi, F. S., Zenilman, M. E., and Shuldiner, A. R. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res., 21: 1047, 1993.
26. Chomczynski, P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques, 15: 532-534, 536-537, 1993.
27. Chou, J., and Chou, T. Multiple drug-effect analysis (program B). In: J. Chou and T. C. Chou (eds.), Dose-effect Analysis with Microcomputers, pp. 19-64. New York: Memorial Sloan-Kettering Cancer Center, 1987.
28. Sabbagh, R., Leclerc, J., Sunderland, M., and Theoret, Y. Chronopharmacokinetic of a 48-hr continuous infusion of doxorubicin to children with acute lymphoblastic leukemia. Proc. Am. Assoc. Cancer Res., 34: 198, 1993.
29. Boos, J., Krumpelmann, S., Schulze Westhoff, P., Euting, T., Berthold, F., and Jurgens, H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J. Clin. Oncol., 13: 2954-2960, 1995.
30. Bennett, C. L., Sinkule, J. A., Schilsky, R. L., Senekjian, E., and Choi, K. E. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res., 47: 1952-1956, 1987.
31. D'Incalci, M., Farina, P., Sessa, C., Mangioni, C., Conter, V., Masera, G., Rocchetti, M., Pisoni, M. B., Piazza, E., Beer, M., and Cavalli, F. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother. Pharmacol., 7: 141-145, 1982.
32. Zar, J. H. Simple linear correlation. In: Biostatistical Analysis, pp. 236-243. Englewood Cliffs, NJ: Prentice-Hall, 1974.
33. Paul, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81: 108-112, 1989.
34. Fleiss, J. L. Statistical Methods for Rates and Proportions, pp. 24-26. New York: John Wiley & Sons, 1981.
35. Hartmann, O., Pinckerton, C. R., Philip, T., Zucker, J. M., and Breatnach, F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J. Clin. Oncol., 6: 44-50, 1988.
36. Komiyama, S., Matsui, K., Kudoh, S., Nogae, I., Kuratomi, Y., Saburi, Y., Asoh, K., Kohno, K., and Kuwano, M. Establishment of tumor cell lines from a patient with head and neck cancer and their different sensitivities to anti-cancer agents. Cancer (Phila.), 63: 675-681, 1989.
37. Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwartz, G. N., Karp, J. E., Burke, P. J., and Kaufmann, S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85: 186-193, 1995.
38. Nakagawara, A., Kadomatsu, K., Sato, S., Kohno, K., Takano, H., Akazawa, K., Nose, Y., and Kuwano, M. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res., 50: 3043-3047, 1990.
39. Hamaguchi, K., Godwin, A. K., Yakushiji, M., O'Dwyer, P. J., Ozols, R. F., and Hamilton, T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 53: 5225-5232, 1993.
40. Sugimoto, Y., Roninson, I. B., and Tsuruo, T. Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol. Cell. Biol., 7: 4549-4552, 1987.
41. Kuroda, H., Sugimoto, T., Ueda, K., Tsuchida, S., Horii, Y., Inazawa, J., Sato, K., and Sawada, T. Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. Int. J. Cancer, 47: 732-737, 1991.
42. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the MDK1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.
43. Bradley, G., Naik, M., and Ling, V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res., 49: 2790-2796, 1989.
44. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
45. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.
46. Kubo, T., Kohno, K., Ohga, T., Taniguchi, K., Kawanami, K., Wada, M., and Kuwano, M. DNA topoisomerase IIα gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res., 55: 3860-3864, 1995.
47. Chan, V. T. W., Ng, S. W., Eder, J. P., and Schnipper, L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese Hamster ovary cell line. J. Biol. Chem., 268: 2160-2165, 1993.
48. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
49. Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253-3259, 1994.
50. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
51. Yao, K., Godwin, A. K., Ozols, R. F., Hamilton, T. C., and O'Dwyer, P. J. Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res., 53: 3662-3666, 1993.
52. Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R. C., and Hamilton, T. C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol., 37: 4597-4600, 1988.
53. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest., 87: 772-777, 1991.
54. Loh, S. Y., Mistry, P., Kelland, L. R., Abel, G., and Harrap, K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66: 1109-1115, 1992.